New Research on HER2-Positive Breast Cancer

Video
Conference|American Society of Clinical Oncology Annual Meeting (ASCO)

Dr. Gianni has been involved with new drug therapies in medical oncology for some time, and in this interview he discusses the changing use of breast cancer treatments, neoadjuvant regimens, and research and developments on HER2-positive breast cancer.

Dr. Luca Gianni, director of medical oncology and coordinator of the New Treatments' Development Programme at the Istituto Nazionale Tumori, Milano, Italy, and the 2011 recipient of the Gianni Bonadonna Breast Cancer Award for his achievements in advancing the field of breast cancer research.

Dr. Gianni has been involved with new drug therapies in medical oncology for some time, and in this interview he discusses the changing use of breast cancer treatments, neoadjuvant regimens, and research and developments on HER2-positive breast cancer.

Recent Videos
Patients with mediastinal lymph node involved-lung cancer may benefit from chemoimmunotherapy in the neoadjuvant setting.
Stressing the importance of prompt AE disclosure before they become severe can ensure that a patient can still undergo resection with curative intent.
Thomas Marron, MD, PhD, presented a session on clinical data that established standards of care for stage II and III lung cancer treatment at CFS 2025.
Sonia Jain, PhD, stated that depatuxizumab mafodotin, ABBV-221, and ABBV-321 were 3 of the most prominent ADCs in EGFR-amplified glioblastoma.
Skin toxicities are common with targeted therapies for GI malignancies but can be remedied by preventative measures and a collaboration with dermatology.
Computational models help researchers anticipate how ADCs may behave in later lines of development, while they are still in the early stages.
ADC payloads with high levels of potency can sometimes lead to higher levels of toxicity, which can eliminate the therapeutic window for patients with cancer.
According to Greg Thurber, PhD, target-mediated uptake is the biggest driver of efficacy for antibody-drug conjugates as a cancer treatment.
Antibody-drug conjugates are effective, but strategies such as better understanding the mechanisms of action may lead to enhanced care for patients with cancer. Antibody-drug conjugates are effective, but strategies such as better understanding the mechanisms of action may lead to enhanced care for patients with cancer.
Related Content
According to Toru Kondo, PhD, EVA1-ADC is able to target glioblastoma-initiating cells while sparing normal cells and stem cells during treatment.

Will Targeting EVA1 With ADCs Eliminate Glioblastoma-Initiating Cells?

Tim Cortese
November 16th 2025
Article

According to Toru Kondo, PhD, EVA1-ADC is able to target glioblastoma-initiating cells while sparing normal cells and stem cells during treatment.

Experts highlight the top 5 presentations from ESMO 2025 that may have long-term clinical implications for genitourinary cancer management.

What Were The Most Impactful GU Oncology Data From ESMO 2025?

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD
November 6th 2025
Podcast

Experts highlight the top 5 presentations from ESMO 2025 that may have long-term clinical implications for genitourinary cancer management.

Data show that XCR1-positive conventional type 1 dendritic cells may play a role as mediators of response to atezolizumab in extensive-stage SCLC.

Atezolizumab/Vaccine Combo May Show Long-Term Survival in ES-SCLC

Russ Conroy
November 15th 2025
Article

Data show that XCR1-positive conventional type 1 dendritic cells may play a role as mediators of response to atezolizumab in extensive-stage SCLC.

Presenting investigators at ESMO Congress 2025 highlight findings from clinical trials assessing novel therapeutics across different disease types.

What Were the Key Presentations at ESMO 2025? Oncology Experts Discuss

Sara A. Hurvitz, MD;Xiuning Le, MD, PhD;Erica L. Mayer, MD, MPH
October 27th 2025
Podcast

Presenting investigators at ESMO Congress 2025 highlight findings from clinical trials assessing novel therapeutics across different disease types.

At 1 and 2 years, the progression-free survival rates were higher with nivolumab plus ipilimumab vs pembrolizumab in patients with cutaneous melanoma.

Nivolumab/Ipilimumab Improves Real-World Melanoma Outcomes Vs Pembrolizumab

Russ Conroy
November 12th 2025
Article

At 1 and 2 years, the progression-free survival rates were higher with nivolumab plus ipilimumab vs pembrolizumab in patients with cutaneous melanoma.

Two studies showed that 1-time cell therapies can elicit complete tumor regression in patients with advanced epithelial cancers.

Novel T-Cell Therapies Yield Decade-Long Remission in Epithelial Cancer

Tim Cortese
November 11th 2025
Article

Findings from 2 studies showed that onetime cell therapies can elicit complete tumor regression in patients with advanced epithelial cancers.